drugset / Trial / NCT00420498

Effects of Atomoxetine on Cognitive Function in Schizophrenia

NCT00420498

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the effects of atomoxetine (Strattera™) on prefrontal cognitive functioning in persons with schizophrenia. Secondarily, the effects of atomoxetine on positive and negative symptoms and on cigarette smoking consumption in persons with schizophrenia will be examined.

Timeline

Start
2005-08
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 40 mg
Subject Atomoxetine Other / unclassified 80 mg

Indications